SecBot SecBot
8-K ·Filed Apr 16, 2026

RVMDW

Revolution Medicines, Inc.
NEUTRAL
Impact 6/10
Horizonweeks Processed7mo ago SEC0001193125-26-159289
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor the use of proceeds for advancement of product candidates and potential M&A activity. The convertible notes offering closing the next day could impact capital structure and future dilution if converted.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.88
T+0 close · Apr 16, 2026 · via day close
Latest settled
+377.66%
T+60 · $8.98
Vs SPY
+371.52%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 17 $1.88entry
  2. T+1 · 7mo ago 0.00%α +0.19% · $1.88
  3. T+5 · 7mo ago 0.00%α −0.55% · $1.88
  4. T+20 · 6mo ago 0.00%α −5.37% · $1.88
  5. T+60 · 4mo ago +377.66%α +371.52% · $8.98
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revolution Medicines raised approximately $1.65 billion through a public offering of 12.15 million common shares at $142.00 per share, alongside a separate $500 million convertible note offering. The proceeds will fund R&D, commercialization of product candidates, and general corporate purposes.

Key Facts

  • Company issued 12,147,887 shares of common stock (10,563,381 base + 1,584,506 option) at $142.00 per share
  • Net proceeds from equity offering estimated at $1.65 billion after underwriting discounts and expenses
  • Concurrent $500 million offering of 0.50% convertible senior notes due 2033
  • Proceeds to be used for R&D, potential commercialization of product candidates, general corporate purposes, and potential acquisitions
  • Equity offering closed on April 16, 2026; convertible note offering expected to close April 17, 2026

Financial Impact

Raised $1.65 billion from equity offering and $500 million from convertible notes, totaling $2.15 billion in gross proceeds

cashdilutiondebt

Risk Factors

  • Dilution from issuance of new shares
  • Future dilution if convertible notes are converted to equity
  • Execution risk in R&D and commercialization efforts

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-159289
Document: d95226d8k.htm0001193125-26-159289
Document: d95226dex51.htm0001193125-26-159289
Document: 0001193125-26-159289-index-headers.html0001193125-26-159289
Document: 0001193125-26-159289-index.html0001193125-26-159289
Document: 0001193125-26-159289.txt0001193125-26-159289

Track record

8 reports on RVMDW

Performance horizon

0 of 3 bullish or bearish reports moved the stock their way by T+60. Best: 0.00% at T+1 after the Apr 15, 2026 report. 0 of 3 went positive at some point.

Filters
  1. Apr 17, 202630w ago 8-K Bearish 8/10 Entry $1.88 to $9.07 ▼ −382.45% −375.67% vs SPY
  2. Apr 16, 202630w ago 8-K Neutral 6/10 Viewing Entry $1.88 to $8.98 ▲ +377.66% +371.52% vs SPY
  3. Apr 15, 202630w ago 424B5 Neutral 6/10 Entry $1.88 to $8.96 ▲ +376.60% +369.55% vs SPY
  4. Apr 15, 202630w ago 424B5 Bearish 7/10 Entry $1.88 to $8.96 ▼ −376.60% −369.55% vs SPY
  5. Apr 15, 202630w ago 144 Bearish 6/10 Entry $1.88 to $8.96 ▼ −376.60% −369.55% vs SPY
  6. Apr 13, 202631w ago 424B5 Bearish 7/10 Entry $1.88 No price data
  7. Apr 13, 202631w ago 424B5 Bearish 7/10 Entry $1.88 No price data
  8. Apr 13, 202631w ago 8-K Bullish 8/10 Entry $1.88 No price data
Showing 8 of 8

US Market Status

Market Closed · Opens in 7h 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 16, 2026